danafarbernews.bsky.social - Profile | ThreadSky | a Reddit-style client for Bluesky

New treatments give hope to patients with pancreatic cancer. Brian Wolpin, MD, MPH, director of the Gastrointestinal Cancer Center @danafarber.bsky.social, spoke with @wsj.com: “The hope really in the field is that these drugs will have some effectiveness and give us a foothold.” bit.ly/3QHJ0OV

submitted 16 hours ago • 0 comments

New research in @cp-cell.bsky.social from @danafarber.bsky.social’s Bruce Spiegelman, PhD, @spiegelmanlab.bsky.social identified that in obesity, Rbm43 loss improves glucose tolerance, reduces adipose inflammation and suppresses activation of the innate immune sensor cGAS-STING. bit.ly/4icQ0Pq

submitted 1 day ago • 0 comments

New research led by @danafarber.bsky.social’s Bradley Bernstein, MD, PhD, featured in @nature.com found four coordinated gene expression programs in immune cells from glioma tumors, including two that could lead to immunotherapy resistance. @broadinstitute.org Read more: bit.ly/3XkI3zD

submitted 2 days ago • 0 comments

“The rare tumor space is an example of where we should think hard about the quality data that we have and how we can help inform future treatments,” @danafarber.bsky.social’s Suzanne George, MD, shared at #RareDiseaseSummit 2025.

submitted 2 days ago • 0 comments

Heading to #ASCOGU25? Click the link below for a list of @danafarber.bsky.social presentations from the ASCO GU Symposium, the leading specialized research and education meeting for GU cancer care. ➡️https://bit.ly/4gI3DFm

submitted 18 days ago • 0 comments

In @statnews.com: 9 patients w/advanced kidney cancer who received an experimental vaccine tailored to tumors’ specific mutations mounted an immune response & remained cancer-free for 3 years. @drchoueiri.bsky.social of @danafarber.bsky.social explains the early-phase clinical trial. bit.ly/4aNK9xs

submitted 23 days ago • 0 comments

Successful anti-cancer immune responses reported in phase 1 trial of a personalized cancer vaccine for #kidneycancer. Research in Nature led by @drchoueiri.bsky.social #PatrickOtt #CatherineWu #DerinKeskin (all of @danafarber.bsky.social) and David Braun of @yalecancer.bsky.social. bit.ly/3CDIT3n

submitted 23 days ago • 1 comment

Research in Cell Genomics led by @danafarber.bsky.social's Bradley Bernstein, MD, PhD, presents an AI transformer model developed in collaboration with Google Advanced Sciences which can predict gene expression. https://bit.ly/42zNVsj

submitted 30 days ago • 0 comments

The list is out! More than 145 @danafarber.bsky.social affiliated faculty are recognized as 2025 Top Doctors by Boston Magazine. Congratulations to all! Press release ➡️ https://bit.ly/40Nw144

submitted 31 days ago • 0 comments

Patients with colon cancer with positive ctDNA tests often face tougher outcomes. Research by @danafarber.bsky.social & Brigham and Women’s Hospital presented at #ASCOGI shows that treatment with a non-steroidal anti-inflammatory drug significantly boosts disease-free survival. bit.ly/4g9zO01

submitted 32 days ago • 0 comments

In a study published in Science Immunology, led by Katie Maurer, MD, PhD, @danafarber.bsky.social researchers have identified key factors that contribute to the success of donor lymphocyte infusion to treat relapse of acute myeloid leukemia after stem cell transplant. Read more: bit.ly/4hurQQg

submitted 32 days ago • 0 comments

Colorectal cancer is the second leading cause of cancer death and the third most common cancer in the U.S. Kimmie Ng, MD, MPH, of @danafarber.bsky.social discusses what you need to know in U.S. News: bit.ly/3CmljrQ

submitted 32 days ago • 0 comments

Join @danafarber.bsky.social’s Brian Wolpin, MD, MPH, for a #PancreaticCancer discussion hosted by @pancan.bsky.social 1/30 at 2pm ET. RSVP at https://bit.ly/42gjjvC

submitted 36 days ago • 0 comments

New research in @nature.com led by @danafarber.bsky.social’s Mohammad Rashidian, PhD, reveals a breakthrough method to detect inflammation using PET imaging. https://bit.ly/3PMi53Z

submitted 37 days ago • 0 comments

Belzutifan plus cabozantinib shows promising antitumor activity in patients with clear-cell renal cell carcinoma not previously treated - research led by @danafarber.bsky.social’s @drchoueiri.bsky.social and published in The Lancet Oncology. bit.ly/4jciWIR

submitted 42 days ago • 0 comments

In @onclive.bsky.social, @danafarber.bsky.social’s Marlise Luskin, MD, MSCE discusses the future of R/R ALL management. https://bit.ly/3WkXaZv

submitted 43 days ago • 0 comments

Princess Catherine's cancer is in remission. @danafarber.bsky.social’s Kimmie Ng, MD, MPH, explains in the @nytimes.com what care may still be needed. https://bit.ly/42eQLmb

submitted 44 days ago • 0 comments

Announcing the 2025 Transatlantic Exchange in Oncology Conference co-chaired by @danafarber.bsky.social's @drchoueiri.bsky.social. Learn more and register at https://bit.ly/4agXnTo

submitted 44 days ago • 0 comments

In a study published in JAMA Oncology, @danafarber.bsky.social researchers led by Gregory Abel, MD, find care after donor stem cell transplant can be safely shared between transplant centers and oncologists. https://bit.ly/40oa1fU

submitted 50 days ago • 0 comments

New research in @nature.com led by Ramesh A. Shivdasani, MD, PhD, of @danafarber.bsky.social gives insight into how intestinal tumors develop. https://go.nature.com/42cMksp

submitted 50 days ago • 0 comments

@danafarber.bsky.social announced the Center for RAS Therapeutics, an initiative to advance treatments for patients with RAS-mutant cancers. Learn more at https://bit.ly/3DIgdqi

submitted 51 days ago • 0 comments

“Thank you for giving us an opportunity to save lives,” Jim Lucia told 7News Boston about his 30-year commitment to donating blood at the Kraft Family Blood Donor Center. https://bit.ly/3DPrYev

submitted 51 days ago • 0 comments

@danafarber.bsky.social has launched the Center for RAS Therapeutics, aiming to study and develop drug therapies for RAS-driven cancers. ➡️ https://bit.ly/41YnNai

submitted 52 days ago • 0 comments

“This is a reminder for all of us that this risk between cancer and alcohol is real," @danafarber.bsky.social’s Robert Haddad, MD, told @NBC10Boston: https://bit.ly/41XSkVG

submitted 53 days ago • 0 comments

Carla Chapman, RN, nominated for @curetoday.bsky.social Extraordinary Healer Award for "making @danafarber.bsky.social a special place for patients.” ➡️ https://bit.ly/4fFG1jZ

submitted 53 days ago • 0 comments

Marios Giannakis of @danafarber.bsky.social talked with @wsj.com about gut-related culprits suspected in driving up cancer cases in young people: https://bit.ly/40j7kfp

submitted 56 days ago • 0 comments

@timrebbeck.bsky.social, Professor of Cancer Prevention at @danafarber.bsky.social, comments on the Surgeon General's new advisory linking alcohol and cancer risk: https://bit.ly/3ZWbgS2

submitted 56 days ago • 0 comments

Congrats to @danafarber.bsky.social's @narjustflorezmd.bsky.social and Scott Armstrong, MD, PhD, who are among BBJ’s 2025 Innovators in Healthcare. https://bit.ly/4gwTLyW

submitted 56 days ago • 0 comments

Riaz Gillani, MD, and Ryan Collins, PhD, of @danafarber.bsky.social report in Science Magazine that rare germline genetic abnormalities increase the risk of pediatric solid cancers. https://bit.ly/3BQ04hK

submitted 57 days ago • 0 comments

Thrilled to share our new paper @Chouchani Lab in Cell; what a great way to end this year! We establish a deep mapping of the zinc-binding human cysteine proteome (ZnCPT) and discover glutathione reductase as zinc-targetable cancer vulnerability. www.cell.com/cell/fulltex...

submitted 59 days ago • 6 comments

ICYMI: In nominating Megan English, RN, for @curetoday.bsky.social Extraordinary Healer Award, a @danafarber.bsky.social colleague praised her knowledge and kindness. https://bit.ly/40cARYk

submitted 60 days ago • 0 comments

In a recent episode of the Polygon Health podcast, @danafarber.bsky.social clinical social worker Adam Lang shares advice and resources for multiple myeloma patients. Listen here: https://www.youtube.com/watch?v=D-fhmrvIWgk&t=5s

submitted 63 days ago • 0 comments

ICYMI: “Deborah DiPrete, RN, is a beacon of compassion and excellence…leaving an indelible mark on the lives of those she touches,” wrote her @danafarber.bsky.social colleagues in nominating DiPrete for @curetoday.bsky.social’s 2024 Extraordinary Healer Award. ➡️ https://bit.ly/4gl07Bh

submitted 64 days ago • 0 comments

ICYMI: Pembroke Academy basketball head coach Mike Donnell shares his colon cancer diagnosis and “journey of getting healthy” while receiving chemo at @danafarber.bsky.social. Listen to his important message about screening & colonoscopy on WKXL NHTalkRadio.com: https://bit.ly/41CSnWN

submitted 66 days ago • 0 comments

A new consensus report from @nationalacademies.org, chaired by @danafarber.bsky.social’s Vish Viswanath, PhD, provides a comprehensive assessment of literature on science misinformation, its origins and impact, and strategies for mitigating its spread and potential harms. ⏩https://bit.ly/49TyCw9

submitted 67 days ago • 0 comments

Congratulations to Ramesh Shivdasani, MD, PhD, of @danafarber.bsky.social for receiving the NET Research Foundation Distinguished Service Award for his outstanding work in NET research. #2024NETRFResearchSymposium #ResearchMatters

submitted 67 days ago • 0 comments

In a @nytimes.com article, Yvan Beaussant, MD, MSc, of @danafarber.bsky.social highlights how psychedelics can reshape how patients face suffering, fostering self-reflection and healing. #PalliativeCare Read more: nyti.ms/4fqtgJW

submitted 71 days ago • 0 comments

Congratulations to Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO, who has been elected 2026-27 @ascopost.bsky.social president. Dr. Mittendorf will be the seventh @danafarber.bsky.social-affiliated physician to serve as president since ASCO was founded in 1964. bit.ly/3VJ5TUQ

submitted 72 days ago • 0 comments

Western lifestyles and the association with younger adults diagnosed with #ColorectalCancer - @danafarber.bsky.social's Marios Giannakis, MD, PhD, featured in Yahoo Life on a recently published study. bit.ly/49HfAcn

submitted 72 days ago • 0 comments

Congratulations to @danafarber.bsky.social's Caroline Block, MD, who was recognized with the prestigious Arthur T. Skarin Award from the Massachusetts Society of Clinical Oncologists for her leadership in oncology and dedication to cancer care. bit.ly/49JSTUJ

submitted 73 days ago • 0 comments

In a study published in JAMA Network Open, Manan Nayak, PhD, and @danafarber.bsky.social researchers found CBD may help reduce cancer-related anxiety. The results are from a Phase 2 clinical trial. Researchers call the findings “intriguing.” Read more here: bit.ly/3ZDdXb8

submitted 73 days ago • 0 comments

SAVE THE DATE: The 4th Transatlantic Exchange in Oncology between @danafarber.bsky.social and Gustave Roussy will take place in Paris on Wednesday March 19, 2025 and will focus on Radiopharmaceuticals. Free registration and Hybrid option! In partnership with Servier and Medscape

submitted 74 days ago • 0 comments

At #SABCS24 @danafarber.bsky.social’s @elmayermd.bsky.social is sharing initial findings from phase 2 trial of neoadjuvant niraparib + dostarlimab. The PARPi/anti-PD1 combo showed encouraging results in patients with HR+ bc & an inherited increased risk of bc, including an 18.8 percent pCR rate.

submitted 77 days ago • 0 comments

At #SABCS24 @danafarber.bsky.social's Otto Metzger, MD, presented late-breaking results of the phase 3 PATINA trial showing addition of palbociclib to standard therapy led to a 15-month improvement in PFS in HR+, HER2+ metastatic breast cancer. @dfcibreastonc.bsky.social bit.ly/41Dj25A

submitted 78 days ago • 0 comments

We join the Telegram & Gazette in celebrating Emilie Center, BSN, RN, a research nurse in @danafarber.bsky.social's Immune Effector Cell Program, for her lifesaving actions to resuscitate a collapsed runner during a fund-raising fun run. Read more at bit.ly/3OThz3K.

submitted 78 days ago • 0 comments

Patients with low-risk DCIS had comparable physical, emotional and psychological outcomes to patients who received standard treatment, according to results of the phase 3 COMET trial presented by @danafarber.bsky.social’s Ann Partridge, MD, MPH, at #SABCS24. @dfcibreastonc.bsky.social bit.ly/3ZLSgXI

submitted 78 days ago • 1 comment